Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise in slowing rare thyroid cancer

NCT ID NCT00410761

Disease control Sponsor: Genzyme, a Sanofi Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tested a daily oral drug called vandetanib (ZD6474) against a placebo in 331 people with advanced medullary thyroid cancer that could not be removed by surgery. The main goal was to see if the drug could delay tumor growth. Researchers also measured how many patients had their tumors shrink. The study is now complete.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vandetanib (also called ZD6474 or ZACTIMA), a once-daily oral tablet
What this could lead to
If successful, this could provide a new treatment option to slow tumor growth in people with advanced medullary thyroid cancer.
What could go wrong
This is a phase 3 trial, but results may not apply to all patients. Side effects from vandetanib can be serious, and the drug may not improve overall survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

331 people

The number who actually took part.

Started

Nov 2006

Finished

Jul 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of unresectable, locally advanced or metastatic hereditary or sporadic Medullary Thyroid Cancer. * Presence of measurable tumor * Able to swallow medication Exclusion Criteria: * Major surgery within 4 weeks before randomization * Last dose of prior chemotherapy received less than 4 weeks prior to randomization * Radiation therapy within the last 4 weeks prior to randomization(with exception of palliative radiotherapy) * Brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days * Significant cardiac events * Previous ZD6474 treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Medullary thyroid cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Carcinoma, Medullary familial medullary thyroid carcinoma medullary thyroid gland carcinoma thyroid cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thyroid cancer

Contacts and locations

Locations

  • Anderson Cancer Center Site Number : 13

    Houston, Texas, 77030, United States

  • Dana Farber Cancer Institute Site Number : 2

    Boston, Massachusetts, 02115, United States

  • Faculdade de Medicina de Ribeirao Preto - USP- Site Number : 2302

    Ribeirão Preto, São Paulo, 14048-900, Brazil

  • Fletcher Allen Health Care Site Number : 21

    Burlington, Vermont, 05401, United States

  • Hospital De Clinicas De Porto Alegre- Site Number : 2301

    Porto Alegre, Rio Grande do Sul, 90035-003, Brazil

  • Investigational Site Number 10

    St Louis, Missouri, 63110, United States

  • Investigational Site Number 1001

    St Leonards, 2065, Australia

  • Investigational Site Number 11

    New Haven, Connecticut, 06510, United States

  • Investigational Site Number 1101

    Brussels, 1000, Belgium

  • Investigational Site Number 1102

    Leuven, 3000, Belgium

  • Investigational Site Number 1201

    Moncton, E1C6Z8, Canada

  • Investigational Site Number 1202

    London, N6A 4L6, Canada

  • Investigational Site Number 1203

    Calgary, T2E7C5, Canada

  • Investigational Site Number 1204

    Sherbrooke, J1H 5N4, Canada

  • Investigational Site Number 1205

    Toronto, M5G2M9, Canada

  • Investigational Site Number 13

    Houston, Texas, 77030, United States

  • Investigational Site Number 14

    Rochester, Minnesota, 55905, United States

  • Investigational Site Number 1401

    Mumbai, 400012, India

  • Investigational Site Number 1402

    Vellore, 632004, India

  • Investigational Site Number 15

    Jacksonville, Florida, 32224, United States

  • Investigational Site Number 1501

    Seoul, South Korea

  • Investigational Site Number 1601

    Pécs, 7624, Hungary

  • Investigational Site Number 17

    Lexington, Kentucky, 40536-0298, United States

  • Investigational Site Number 1701

    Gliwice, 44-101, Poland

  • Investigational Site Number 1702

    Poznan, 60-355, Poland

  • Investigational Site Number 1703

    Warsaw, 02-781, Poland

  • Investigational Site Number 18

    Chicago, Illinois, 60637, United States

  • Investigational Site Number 1801

    Bucharest, Romania

  • Investigational Site Number 19

    Charleston, South Carolina, 29425, United States

  • Investigational Site Number 1901

    Vienna, 1901, Austria

  • Investigational Site Number 2

    Boston, Massachusetts, 02115, United States

  • Investigational Site Number 2001

    Halle, 06120, Germany

  • Investigational Site Number 2002

    Essen, 45122, Germany

  • Investigational Site Number 2005

    Würzburg, 97080, Germany

  • Investigational Site Number 21

    Burlington, Vermont, 05401, United States

  • Investigational Site Number 2101

    Basel, 4031, Switzerland

  • Investigational Site Number 2102

    Bern, CH-3010, Switzerland

  • Investigational Site Number 22

    Portland, Oregon, 97239, United States

  • Investigational Site Number 2301

    Porto Alegre, 90035-003, Brazil

  • Investigational Site Number 2302

    Ribeirão Preto, 14048-900, Brazil

  • Investigational Site Number 2402

    Mexico City, 14000, Mexico

  • Investigational Site Number 2403

    Ciudad Madero, Mexico

  • Investigational Site Number 2404

    México, 06726, Mexico

  • Investigational Site Number 2501

    Pisa, 56124, Italy

  • Investigational Site Number 2502

    Milan, Italy

  • Investigational Site Number 2503

    Naples, 80131, Italy

  • Investigational Site Number 2504

    Siena, 53100, Italy

  • Investigational Site Number 2505

    Roma, 00161, Italy

  • Investigational Site Number 2506

    Catania, Italy

  • Investigational Site Number 2601

    Lisbon, 1099-023, Portugal

  • Investigational Site Number 2602

    Coimbra, 3000-75, Portugal

  • Investigational Site Number 2701

    Odense C, 5000, Denmark

  • Investigational Site Number 2801

    Villejuif, 94800, France

  • Investigational Site Number 2802

    Bordeaux, 33076, France

  • Investigational Site Number 2803

    Lyon, 69373, France

  • Investigational Site Number 2901

    Utrecht, Netherlands

  • Investigational Site Number 2902

    Groningen, Netherlands

  • Investigational Site Number 3

    Little Rock, Arkansas, 72205, United States

  • Investigational Site Number 3001

    Madrid, 28041, Spain

  • Investigational Site Number 3002

    Pamplona, 31008, Spain

  • Investigational Site Number 3003

    Madrid, 28040, Spain

  • Investigational Site Number 3101

    Uppsala, 75185, Sweden

  • Investigational Site Number 3102

    Stockholm, 17176, Sweden

  • Investigational Site Number 3301

    Obninsk, 249036, Russia

  • Investigational Site Number 3401

    Belgrade, 11000, Serbia

  • Investigational Site Number 3402

    Belgrade, Serbia

  • Investigational Site Number 3601

    Prague, 15006, Czechia

  • Investigational Site Number 6

    Cincinnati, Ohio, 45267-0589, United States

  • Investigational Site Number 7

    Detroit, Michigan, 48201, United States

  • Investigational Site Number 8

    San Francisco, California, 94115, United States

  • Investigational Site Number 9

    Aurora, Colorado, 80010, United States

  • Investigational Site Number : 1101

    Anderlecht, 1070, Belgium

  • Investigational Site Number : 1102

    Leuven, 3000, Belgium

  • Investigational Site Number : 1201

    Moncton, New Brunswick, E1C6Z8, Canada

  • Investigational Site Number : 1202

    London, Ontario, N6A 4L6, Canada

  • Investigational Site Number : 1203

    Calgary, Alberta, T2E7C5, Canada

  • Investigational Site Number : 1204

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Investigational Site Number : 1205

    Toronto, Ontario, M5G2M9, Canada

  • Investigational Site Number : 1401

    Mumbai, 400012, India

  • Investigational Site Number : 1402

    Vellore, 632004, India

  • Investigational Site Number : 1501

    Seoul, 03080, South Korea

  • Investigational Site Number : 1601

    Pécs, 7624, Hungary

  • Investigational Site Number : 1701

    Gliwice, 44-101, Poland

  • Investigational Site Number : 1702

    Poznan, Greater Poland Voivodeship, 60-355, Poland

  • Investigational Site Number : 1703

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • Investigational Site Number : 1901

    Vienna, 1901, Austria

  • Investigational Site Number : 2001

    Halle, 06120, Germany

  • Investigational Site Number : 2002

    Essen, 45122, Germany

  • Investigational Site Number : 2005

    Würzburg, 97080, Germany

  • Investigational Site Number : 2101

    Basel, 4031, Switzerland

  • Investigational Site Number : 2102

    Bern, CH-3010, Switzerland

  • Investigational Site Number : 2404

    México, 06726, Mexico

  • Investigational Site Number : 2501

    Pisa, 56124, Italy

  • Investigational Site Number : 2502

    Milan, Italy

  • Investigational Site Number : 2503

    Naples, 80131, Italy

  • Investigational Site Number : 2504

    Siena, 53100, Italy

  • Investigational Site Number : 2505

    Roma, 00161, Italy

  • Investigational Site Number : 2506

    Catania, Italy

  • Investigational Site Number : 2601

    Lisbon, 1099-023, Portugal

  • Investigational Site Number : 2701

    Odense C, 5000, Denmark

  • Investigational Site Number : 2801

    Villejuif, 94800, France

  • Investigational Site Number : 2802

    Bordeaux, 33076, France

  • Investigational Site Number : 2803

    Lyon, 69373, France

  • Investigational Site Number : 2901

    Utrecht, Netherlands

  • Investigational Site Number : 2902

    Groningen, Netherlands

  • Investigational Site Number : 3001

    Madrid, 28041, Spain

  • Investigational Site Number : 3002

    Pamplona, Navarre, 31008, Spain

  • Investigational Site Number : 3003

    Madrid, 28040, Spain

  • Investigational Site Number : 3101

    Uppsala, 75185, Sweden

  • Investigational Site Number : 3102

    Stockholm, 17176, Sweden

  • Investigational Site Number : 3301

    Obninsk, 249036, Russia

  • Investigational Site Number : 3401

    Belgrade, 11000, Serbia

  • Investigational Site Number : 3402

    Belgrade, Serbia

  • Investigational Site Number : 3601

    Prague, 15006, Czechia

  • Mayo Clinic- Site Number : 14

    Rochester, Minnesota, 55905, United States

  • Mayo Clinic- Site Number : 15

    Jacksonville, Florida, 32224, United States

  • Medical University of South Carolina- Site Number : 19

    Charleston, South Carolina, 29425, United States

  • Oregon Health & Science University- Site Number : 22

    Portland, Oregon, 97239, United States

  • The University Of Chicago Site Number : 18

    Chicago, Illinois, 60637, United States

  • The University Of Kentucky Site Number : 17

    Lexington, Kentucky, 40536-0298, United States

  • USCF / Mt Zion Medical Center Site Number : 8

    San Francisco, California, 94115, United States

  • University Arkansas Site Number : 3

    Little Rock, Arkansas, 72205, United States

  • University Of Cincinnati Site Number : 6

    Cincinnati, Ohio, 45267-0589, United States

  • University Of Colorado Health Sciences Center Site Number : 9

    Aurora, Colorado, 80010, United States

  • Washington University School Of Med Site Number : 10

    St Louis, Missouri, 63110, United States

  • Wayne State University / Harper Hospital Site Number : 7

    Detroit, Michigan, 48201, United States

  • Yale University School Medicine Site Number : 11

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.